Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study
Yegerov et al.,
Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a..,
medRxiv, doi:10.1101/2021.01.06.20249091 (Preprint)
Retrospective 1,072 hospitalized patients in Kazakhstan showing no mortality for HCQ treated patients, however only 23 patients received treatment - this result is not statistically significant.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 95.3% lower, RR 0.05, p = 1.00, treatment 0 of 23 (0.0%), control 20 of 1,049 (1.9%), NNT 52, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Yegerov et al., 8 Jan 2021, retrospective, Kazakhstan, preprint, 8 authors, average treatment delay 1.0 days.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.01.06.20249091; this version posted January 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Yegorov S et al.
COVID-19 in Kazakhstan
1
Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19
2
Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study.
3
Sergey Yegorov, PhD1*^, Maiya Goremykina, MD2^, Raifa Ivanova, MD2^, Sara V.
4
Good3, PhD, Dmitriy Babenko, MD3^, Alexandr Shevtsov, PhD4 on behalf of the COVID-
5
19 Genomics Research Group#, Kelly S. MacDonald, MD5,6 and Yersin Zhunussov, MD7
6
on behalf of the Semey COVID-19 Epidemiology Research Group
.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
1
School of Sciences and Humanities, Nazarbayev University, 53 Kabanbay Batyr Ave,
Nur-Sultan, 010000, Republic of Kazakhstan.
2
Department of Rheumatology and Non-Infectious Diseases, Semey Medical University
103 Abai street, Semey, 071400, Republic of Kazakhstan.
3
Department of Biology, University of Winnipeg, 599 Portage Avenue, Winnipeg, MB,
R3B2E9, Canada.
4
National Centre for Biotechnology, 13/5 Kurgalzhynskoye road, Nur-Sultan, 010000,
Republic of Kazakhstan
5
Departments of Medicine, Microbiology & Immunology, Max Rady College of Medicine,
University of Manitoba, 745 Bannatyne Avenue, Winnipeg, MB, R3E 0J9, Canada
6
JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, 745
Logan Avenue, Winnipeg, MB, R3E3L5, Canada
7
Department of Public Health, Semey Medical University, 103 Abai street, Semey,
071400, Republic of Kazakhstan.
22
23
# The members of the COVID-19 Genomics Research Group (CGRG) collaborative group
24
are listed in the appendix pp. 8-9
25
26
The members of the Semey COVID-19 Epidemiology Research Group (SCERG)
collaborative group are listed in the appendix pp. 8-9
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.01.06.20249091; this version posted January 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Yegorov S et al.
COVID-19 in Kazakhstan
1
* Corresponding author contact emails and phone:
2
sergey.yegorov@nu.edu.kz, yegorovsrg@gmail.com, +77770211487
3
^ These authors contributed equally to this work
4
5
Key words: COVID-19; SARS-CoV-2; clinical characteristics; disease risk factors,
6
molecular epidemiology; Central Asia; Kazakhstan.
2
medRxiv preprint doi: https://doi.org/10.1101/2021.01.06.20249091; this version posted January 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Yegorov S et al.
COVID-19 in Kazakhstan
1
ABSTRACT.
2
Background: The earliest coronavirus disease-2019 (COVID-19) cases in Central Asia
3
were announced in March 2020 by Kazakhstan. Despite the implementation of aggressive
4
measures to curb infection..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit